Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Download Title Speakers Chairs 2011 MCS SESSIONS
Document related concepts
no text concepts found
Transcript
Title Speakers 2011 MCS SESSIONS Risky business: Heart failure, transplant, and MCS Assessment of HF risk Assessment of transplant risk Assessment of transplant risk in Europe Assessment of MCS risk Assessing the risk of what? Modeling risk for individual patients Case presentations Joe Rogers, USA Axel Rahmel, The Netherlands Wayne Levy, USA David Brad Dyke, USA Bruno Meiser, Germany Katherine Lietz, USA Keith Aaronson, USA David Naftel, USA Chetal Patel, USA A. Stepanenko, Germany Jeff Teuteberg, USA George Wieselthaler, USA/Austria When does "less sick" = "sick enough" for MCS? How many walking wounded are there? Does exercise testing evaluate disease severity in the era of beta blockade? Quality of life as a potential indication for VAD Should inotropic therapy come before VAD What are the tipping points? Is there a different threshold for a VAD when transplant is not an option? Differences in national registry perspective Quality of life in the interventions for endstage thoracic organ disease MCSD (one of many talks) Randy Starling, USA Stuart Russell, USA Eldrin Lewis, USA Debra Isaac, USA Lee Goldberg, USA Michael Acker, USA Ileana Pina, USA Kathy Grady, USA Management of the failing right ventricle at the time of MCS implant Assessing right ventricular function Guy MacGowen, UK Biventricular failure: Lessons learned from Robert Kormos, USA INTERMACS Current TAH/Paracoporeal BiVAD support options Pascal Leprince, France Management of the tricuspid valve in the face of biventricular failure When is temporary RVAD support enough New continuous flow TAH/BiVAD support strategies Update on pediatric MCS Thomas Krabatsch, Germany Robert Kormos, USA Carmelo Milano, USA Vivek Rao, USA Roland Hetzer, Germany Soon Park, USA Matthias Loebe, USA VADs gone bad Inlet canula obstruction The recurring infection The leaking valve Where, oh where am I bleeding from Chairs Mattias Loebe, USA Margarita Camacho, USA Nader Moazami, USA Ulrich Jorde, USA Elizabeth Blume, USA Roland Hetzer, Germany Anatomy and physiology in congential heart disease complicating MCS Current device options for pediatric patients and single ventricle implant techniques Update on the North American Berlin Heart experience Update on the NIH PumpKIN trial Eric Devaney, USA Michael Hubler, Germany Holer Buchholz, Canada Bart Griffith, USA OH Frazier, USA Steven Tsui, UK It's alive! Mycardial recovery during MCS Disconnect between cellular and clinical recovery Ken Margulies, USA Myocardial recovery during LVAD support: pulsatile v continuous flow Techniques to facilitate device explantation following recovery T Krabatsch, Germany E Potapov, Germany Palliative care across the illeness trajectory The MCS coordinator perspective on palliative care (among others) Annemarie Kaan, Canada Stephanie Moore, USA Emma Birks, USA/UK Standardized MCS guidelines: We have arrived Overview and goals of the guidelines Guidelines at a glance Implementation, impact, and future of standardized guidelines Stephanie Moore, USA Jeff Morgan, USA Emma Birks, USA/UK Jeff Teuteberg, USA Mariell Jessup, USA Waiting in the wings - advanced heart failure Who are the patients at referral centers? Who wants a VAD? What is current optimal medical therapy Quality of life and functional capacity Co-morbidities in heart failure Jennifer Cowger, USA Garrick Stewart, USA Eddie Rame, USA Parag Patel, USA Michelle Kittleson, USA 2012 MCS SESSIONS Optimizing outcomes in patients with right heart failure in need of MCS Predicting right heart failure after LVAD Stephan Schueler, UK implantation RV dysfunction in MCS: What is the transcript Eddie Rame, USA signature of RV/LV in mechanicaly assisted patients Triage with medicines Michael Givertz, USA Triage with BiVADs T Krabatsch, Germany TAH is it Vig Kasirajan, USA Right heart failure late after implant Vivek Rao, USA Cardiogenic shock before and after heart transplantation Cardiogenic shock - how long should the ECMO bridge be? What is the direction of the bridge in cardiogenic shock? David Feldman, USA Ugolino Livi, Italy Nader Moazami, USA Nicholas Smedira, USA Aly El Banayosy, USA Pascal Leprince, France Extracoporeal mechanical support and community hospitals: how to make it work What is the best surgical option in the setting of PGD? Surgical technique of ECMO placement - balance between invasiveness and effectiveness Christof Schmid, Germany Ivan Netuka, Czech Republic Arnt Fiane, Norway Matthias Loebe, USA Martin Strueber, Germany New devices, new approaches Axial v centrifugal pumps LVAD: partial v. full flow support VAD therapy in heart failure with preserved systolic function Machine or biology? The future for a patient with a failing heart is with machines Machine or biology? The future for a patient with a failing heart is with stem cells Machine or biology? The future for a patient with a failing heart is with xenotransplantation MCS in congential heart disease and pediatrics Implant VADs in children and adults with congenital heart disease Is two better than one? Indications for BiVAD v. LVAD placement in children Beyond the surgery - preventing thromboembolic complications during long-term VAD support Frank Pagani, USA Bartley Griffith, USA Soon Park, USA James Kirklin, USA Andre Terzic, USA C McGregor, UK Ivan Rebeyka, Canada Christopher Almond, USA David Morales, USA Holger Buchholz, Canada Patty Massicotte, Canada VAD options for the single ventricle Olaf Reinhartz, USA Heart transplant or VAD in children and adults with Robert Jaquiss, USA congenital heart disease - strategies for improving transplant outcomes Going home: hospital discharge on VAD support William Wrightson, UK in children The longer the better - chronic medical management of MCS Fine tuning pump performance Arrhythmia management : beyond amiodarone Aortic insufficiency: an achilles heel for long-term support Long-term infection prevention GI bleeding: what is the optimal strategy for diagnosis and management? Getting back to life: sex, driving, and rock-n-roll Evgenij Potapov, Germany Sudhir Kushwaha, USA Mark Slaughter, USA Salpy Pamboukian, USA Roland Hetzer, Germany Margaret Hannan, Ireland Jeff Teuteberg, USA Karl Nelson, USA Lifecycle journey in advanced heart failure and transplantation Pre-transplant journey: BTT with malfunction due Paul Nolan, USA to thrombosis (among others) Focus on caregivers Family caregivers of MCS (among others) Judy Currey, Australia Mechanic circulatory support - when is it too soon or too late? Ambulatory heart failure - when has medical therapy failed? Patient risk - heart failure and VAD operation, where is the sweet spot? MCS in the less sick patients - where will REVIVEIT fit? MCS should be the first choice for paients with end-stage HF Pro and con debate Jan Pirk, Czech Republic Ryan Tedford, USA JoAnn Lindenfeld, USA Garrick Stewart, USA Keith Aaronson, USA Joseph Woo, USA Andreas Zuckermann, Austria Joe Rogers, USA Hans Lehmkuhl, Germany MCS recovery - how do we get there? Effects of LVAD unloading on the myocardial function and structure Targeted adjuvant therapies to enhance LVADinduced reverse remodeling How to monitor the heart during LVAD unloading Stavros Drakos, USA Emma Birks, USA Simon Maybaum, USA Predictors of LVAD-induced sustained myocardial Michael Dandel, Germany recovery Felix Perez-Villa, Spain Lynne Stevenson, USA Following the RV through thick and thin Treatment of RV failure after LVAD or transplant Mauro Rinaldi, Italy Assessment of CRV function during RV support (among others) Marc Simon, USA Plenary session Remote monitoring of MCS (among others) Jan Gummert, Germany
Related documents